Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...

Alpharetta, Georgia Wednesday, February 12, 2025, 16:30 Hrs [IST] ...

Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% reduction in anti-VEGF IVT treatment in fellow eyes of bilateral ...

BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular”), a biopharmaceutical ...

REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target ...

The 36-week trial was a randomized, double-masked, parallel-group, active-controlled, multicenter evaluating CLS-AX (axitinib ...

Ocular Therapeutix, Inc. has announced its participation in the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting, scheduled for February 8, 2025, where it will present new findings ...

were presented at the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025. The data were presented by Michael Singer, M.D., Clinical Professor of Ophthalmology at ...

Fennel seeds contain anethole, a compound that has been found to exhibit anti-cancer properties by inhibiting cancer cell ...

D Molecular (FDMT) presented 52-week wet age-related macular degeneration Phase IIb results at this weekend’s Angiogenesis, Exudation, and ...

Clearside Biomedical (CLSD) announces that two subgroup analyses were presented from the ODYSSEY Phase 2b clinical trial at the Angiogenesis, ...

I was recently invited to try SomaCell, a groundbreaking new FDA-cleared treatment that promises to take years off your face ...